MRI progression (12 weeks) | MRI progression (24 weeks) | X-ray progression (52 weeks) | ||||
---|---|---|---|---|---|---|

No | Yes | No | Yes | No | Yes | |

All participants | (N=190) | (N=194) | (N=420) | |||

MTX monotherapy | 46 | 16 (26%) | 47 | 17 (27%) | 97 | 44 (31%) |

Combination MTX+GLM | 109 | 19 (15%) | 110 | 20 (15%) | 213 | 66 (24%) |

p value | 0.07 | 0.06 | 0.1 | |||

Estimated group N | 229 | 196 | 581 | |||

Synovitis >5 | (N=147) | (N=152) | ||||

MTX monotherapy | 30 | 15 (33%) | 32 | 16 (33%) | ||

Combination MTX+GLM | 85 | 17 (17%) | 86 | 18 (17%) | ||

p Value | 0.02 | 0.03 | ||||

Estimated group N | 117 | 127 | ||||

Bone oedema >5 | (N=109) | (N=110) | ||||

MTX monotherapy | 20 | 11 (35%) | 20 | 12 (38%) | ||

Combination MTX+GLM | 64 | 14 (18%) | 65 | 13 (17%) | ||

p Value | 0.05 | 0.02 | ||||

Estimated group N | 110 | 80 |

GLM, golimumab; MTX, methotrexate; RAMRIS, rheumatoid arthritis MRI score; vdHS, van der Heijde-Sharp.